A limited role for regulatory T cells in post-ischemic neovascularization

A.A. Hellingman, L.E.P.M. van der Vlugt, M.A. Lijkwan, A.J.N.M. Bastiaansen, T. Sparwasser, H.H. Smits, J.F. Hamming, P.H.A. Quax

A Department of Vascular Surgery, Leiden University Medical Center, Leiden, The Netherlands
B Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands
C Institute of Infection Immunology, TWINCORE Center of Experimental and Clinical Infection Research, Feodor-Lynen-Strasse, Hannover, Germany
D Eindhoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands

Received: November 30, 2010; Accepted: March 1, 2011

Abstract

Recently, it was demonstrated that arteriogenesis is enhanced in mice deficient in regulatory T cells (CD4^+CD25^+FoxP3^+ T cell), which can suppress effector T cell responses. The present study investigates the effects of these regulatory T cells on arteriogenesis in more detail by either specific expanding or depleting regulatory T cells. Hind limb ischemia was induced by electro-coagulation of the femoral artery in mice. Regulatory T cells were either expanded by injecting mice with a complex of interleukin (IL)-2 with the IL-2 monoclonal antibody JES6–1, or depleted by anti-CD25 antibody or diphtheria toxin injections in DEREG mice (depletion of regulatory T cells). Blood flow restoration was monitored using laser Doppler perfusion imaging. Collateral arteries were visualized by immunohistochemistry. Regulatory T cell expansion led to a moderate though significant suppression of blood flow restoration after ischemia induction. Surprisingly, depletion of regulatory T cells resulted in minor increase on blood flow recovery. However, collateral and capillary densities in the post-ischemic skeletal muscle were significantly increased in DEREG mice depleted for regulatory T cells. The presence of regulatory T cells after ischemia induction when analysed in non-depleted DEREG mice could be demonstrated by green fluorescent protein staining only in lymph nodes in the ischemic area, and not in the ischemic muscle tissue. The current study demonstrates that, even under conditions of major changes in regulatory T cell content, the contribution of regulatory T cells to the regulation of the arteriogenic response is only moderate.

Keywords: regulatory T cells • arteriogenesis • neovascularization • hind limb ischemia

Introduction

Numerous studies have implicated that the immune system plays a major role in arteriogenesis [1, 2]. A specific cell of the immune system, the regulatory T cell (CD4^+CD25^+FoxP3^+ T cell), is specialized in the suppression of effector T-cell pathogenic immune responses. Regulatory T cells control T-cell homeostasis [3, 4] and are indispensable for balancing immune responses [5, 6]. Accumulating evidence suggests an important role of regulatory T cells in the control of atherosclerotic lesion development and progression [7–9]. Recently, Zouggari et al. [10] assessed for the first time the role of regulatory T cells on blood flow recovery after ischemia induction in mouse models with a reduced regulatory T cell number and function [8, 10–13]. They reported a key role of regulatory T cells in post-ischemic neovascularization. Post-ischemic blood flow recovery was significantly enhanced in these mice up to 70% 21 days after ischemia induction as compared to slow recovery in control mice [10]. Because the mouse models used for depletion of regulatory T cells may also show effect on other T cell subtypes besides the regulatory T cell [14], a more detailed and specific analysis of the role of the regulatory T cell in arteriogenesis is required. The question remains how regulatory T cells regulate arteriogenesis and moreover whether regulatory T cell expansion has effects on...
arteriogenesis. The effect of expanding regulatory T cell number on arteriogenesis can be studied using the recently described method for in vivo expansion of regulatory T cells by Webster et al. [15]. Injecting mice with a complex of interleukin (IL)-2 mixed with JES6–1 IL-2 monoclonal antibody (mAb) led to a marked increase in regulatory T cell number. This approach caused selective expansion of regulatory T cells with little or no change in other cells, making it superior to other attempts [10, 15] to increase regulatory T cells [15].

Next to expansion of regulatory T cell number, depletion of regulatory T cells is highly informative. The standard approach is depletion of CD25+ cells. But this approach has its shortcomings because anti-CD25 treatment does not result in a selectively depletion of regulatory T cells only [7, 16], but also affects activated T cells [17], dendritic cells (DCs) [18] and natural killer (NK) cells [19]. Recently, a more powerful approach to fully deplete regulatory T cells was described by Lahl et al. [20]. They generated DEREG mice (depletion of regulatory T cells), expressing a diphtheria toxin (DT) receptor/green fluorescent protein (GFP) fusion protein under the control of the FoxP3 gene locus. DT injections in DEREG mice allowed for highly specific and up to 95–98% depletion of FoxP3+ regulatory T cells at any desired time-point without disease development [20].

In the present study, the contribution of regulatory T cells in the arteriogenic response was studied by major modulations in regulatory T cell number in vivo. Regulatory T cell numbers in mice were either increased by injecting mice with IL-2 mixed with an IL-2 mAb or decreased by anti-CD25 antibody or DT injections in DEREG mice. Furthermore, using the GFP-labelled regulatory T cells in DEREG mice, the presence of regulatory T cells in the ischemic muscle tissue will be analysed in detail.

Material and methods

Experimental animals

Ten-week-old C57Bl/6 mice (The Jackson Laboratory, Bar Harbor, ME, USA) were used (10 mice per group). Furthermore, DEREG mice (Leiden University Medical Center, Leiden, The Netherlands), aged 9–16 weeks, were used. Experiments were approved by the committee on animal welfare of our institute.

Modulation of regulatory T cell levels

Regulatory T cell expansion
To increase regulatory T-cell number, C57Bl/6 mice were injected with 1 μg IL-2 (PeproTech, Inc., Rocky Hill, NJ, USA) mixed with 5 μg IL-2 mAb (clone JES6–1A12; R&D Systems, Minneapolis, MN, USA) [15]. Mice were injected at days 3, 2 and 1 before ischemia induction and two times a week after the surgical procedure. Expansion of regulatory T cell level was monitored by fluorescence-activated cell sorting (FACS) (mouse regulatory T-cell staining kit; ebioscience Inc., San Diego, CA, USA).

Regulatory T-cell depletion
Depletion of regulatory T cells is accomplished by treating C57Bl/6 mice with CD25-depleting PC61 antibody [21]. A total of 100 μg per mouse was injected at day 1 before ischemia induction and repeated once per week after surgery.

DEREG mice express a DT receptor/GFP fusion protein under control of the FoxP3 gene locus, leading to selective depletion of FoxP3+ regulatory T cells after injection of 1 μg DT per mouse [22]. Depletion of regulatory T cells was monitored by FACS analyses (mouse regulatory T cell staining kit; ebioscience).

Surgical procedure

In the regulatory T-cell expansion experiments, blood flow was expected to be suppressed. In order to distillate an attenuated blood flow recovery compared to well-known fast recovery of control mice, single electro-coagulation of the femoral artery was performed. Mice depleted for regulatory T cells were expected to have accelerated blood flow recovery compared to controls that are well-known good responders. Therefore, in this situation, double electro-coagulation of both the femoral artery and iliac artery was performed because the double electro-coagulation resulted in a larger therapeutic window [23]. This enables a better analysis of enhancing effects on arteriogenesis.

Before surgery, mice were anesthetized with an intraperitoneal injection of a combination of Midazolam (5 mg/kg; Roche Diagnostics, Almere, The Netherlands), Medetomidine (0.5 mg/kg; Orion Corporation, Espoo, Finland) and Fentanyl (0.05 mg/kg; Janssen Biologics B.V., Leiden, The Netherlands). Unilateral hind limb ischemia was performed as described before [23]. After surgery the skin was closed with 6–0 Ethilon sutures.

Laser Doppler perfusion imaging (LDPI)

Blood flow was measured before ischemia induction, immediately after ischemia induction and 3, 7, 14, 21 and 28 days after surgery in the ischemic and non-ischemic paws, using LDPI (Moor Instruments, Axminster, Devon, UK). LDPI is performed with a beam from a 2 mW helium laser that sequentially scans tissue surface to a depth of a few hundred micrometres. The penetration depth of the laser beam thus allows measurements of superficial skin perfusion only. Therefore, perfusion in both paws (from the ankle to the base of toes) is obtained at baseline and serially over 4 weeks after hind limb ischemia induction. Paw perfusion functions as a resultant of limb perfusion recovery. Furthermore, to avoid measuring increased perfusion near the wound, it is preferable to exclusively select the paws, more distally, as the region of interest for analyses. Each animal served as its own control. Perfusion was expressed as a ratio of the ischemic to non-ischemic limb, as described previously [23].

Histological analysis

Animals were killed 14 and 28 days after ischemia induction and calf and adductor muscles (from ischemic and non-ischemic paw) were removed and fixed with 4% formaldehyde and paraffin embedded. Serial 5 μm cross-sections were generated. Sections were re-hydrated and endogenous hydrogen peroxide activity was blocked for 20 min. in methanol containing 0.3% hydrogen peroxide. Capillaries and collaterals were visualized using antibodies recognizing CD31 on endothelial cells or α-smooth muscle actin (SMA) in smooth muscle cells, respectively.
For CD31 labelling, sections were pre-incubated with trypsin (30 min./37°C), incubated overnight with primary antibody (rat antimouse CD31Ab, dilution 1:200; BD Biosciences B.V., Breda, the Netherlands) followed by a biotin-conjugated secondary antibody (goat anti-rat, dilution 1:300; AbCam, Cambridge, UK). The reaction was enhanced by tyramine amplification and the avidin–biotin–horseradish–peroxidase system (DakoCytomation, Glostrup, Denmark) and visualized by NovaRED (Vector Laboratories Inc., Burlingame, CA, USA).

For SMA labelling, tissue sections were incubated overnight with anti-αSMA (mouse anti-human, dilution 1:800; DAKO, Glostrup, Denmark) without antigen retrieval. Labelling was followed by an HRP-conjugated secondary antibody (rabbit antimouse, dilution 1:300; DAKO).

For staining of GFP+ regulatory T cells in DEREG mice, adductor muscle slides were incubated with anti-GFP (rabbit antimouse, dilution 1:4000; Invitrogen, Breda, the Netherlands) without antigen retrieval. Labelling was followed by an HRP-conjugated secondary antibody (donkey anti-rabbit, dilution 1:300; Invitrogen).

For tracing of GFP+ regulatory T cells in DEREG mice, adductor muscle slides were incubated with anti-GFP (rabbit antimouse, dilution 1:4000; Invitrogen, Breda, the Netherlands) without antigen retrieval. After overnight incubation, labelling was followed by a biotin-conjugated secondary antibody (donkey anti-rabbit, dilution 1:300). As a positive control, a slide of GFP+ cardiac muscle tissue was used.

All sections were counterstained with haematoxylin. Isotype control antibodies were used as controls. Quantification of labelled tissue sections was performed with ImageJ (nine sections per mouse were analysed to obtain the mean per animal, 10 animals per group were measured).

Flow cytometry

Cells were labelled with fluorescein isothiocyanate (FITC) anti-CD4 (eBioscience) and Allophycocyanin (APC) anti-CD25. An intracellular FoxP3 staining was performed with PE anti-FoxP3 (eBioscience). Regulatory T cell labelling was analysed by flow cytometry on a LSRII FACS apparatus (Becton Dickinson B.V., Breda, the Netherlands) and analysed with BD FACS DIVA software.

In vitro suppression assay

Peripheral lymph nodes were removed from three DEREG mice after repetitive DT injections during 3 weeks and in three DEREG mice without DT injections. The functional suppression assay was described as performed by Rausch et al. [24].

Statistical analysis

Results are expressed as mean ± S.E.M. Comparisons between means were performed with an independent t-test. P-values <0.05 were considered statistically significant. All calculations were performed in SPSS 16.0.

Results

Expansion of regulatory T cells results in impaired post-ischemic blood flow recovery

The effect of expanding regulatory T cells on arteriogenesis in mice is unknown. Regulatory T cell numbers were expanded in the hind limb ischemia mouse model by injecting mice with IL-2 mixed with an IL-2 mAB. Injections of IL-2-mAB complex led to a 2-fold expansion of regulatory T cells in the peripheral blood (Fig. 1A). Mice treated with injections of IL-2-mAB complex (n = 10) showed significant attenuated blood flow recovery up to 20% at days 7 and 14 after ischemia compared to controls (n = 10), indicating that an increase in regulatory T cell number was responsible for a suppression in blood flow recovery after hind limb ischemia (Fig. 1B). Furthermore, mice treated with IL-2-mAB complex showed a significant lower number of α-SMA-expressing collaterals in the post-ischemic adductor muscle as compared to controls (Fig. 1C).

Decline of regulatory T cells using anti-CD25 did not show any effect on blood flow recovery

Next to expansion of regulatory T cells, we were interested in the effects of regulatory T cell depletion too. Originally, regulatory T cells were identified by the expression of CD25 and numerous in vivo experiments studying regulatory T cells have been performed with depleting antibodies directed against CD25 [25, 26]. No effect of anti-CD25 antibody treatment (n = 10) on blood flow recovery was observed as compared to controls (n = 10) after single electro-coagulation of the artery (Fig. 2A). The moderate effects of the depletion on arteriogenesis could be obscured by the rapid response of these mice. Although the therapeutic window was increased after double electro-coagulation of both the femoral artery and iliac artery, CD25 depleting antibody-injections (n = 10) did not result in any alteration of blood flow recovery as compared to controls (n = 10) (Fig. 2B). FACS analyses showed 87% depletion of regulatory T cells directly after the surgical procedure. However, regulatory T cell levels returned to half of normal levels 1 week after ischemia, but at that moment, again anti-CD25 was injected into these mice (Fig. 2C). Thus with anti-CD25 antibody treatment, a minimal CD25 level was present all the time. So, a better approach to deplete regulatory T cells was needed.

Selective depletion of regulatory T cells led to moderate effects on arteriogenesis

Depletion of FoxP3+ T cells in DEREG mice.

DEREG mice allowed depletion of FoxP3+ regulatory T cells upon DT injections. Because two consecutive DT injections led to almost complete [20], but short (<6 days) depletion of regulatory T cells (Fig. 3A), DEREG mice were treated with repetitive DT injections. FACS analyses showed up to 98% depletion of FoxP3+ regulatory T cells for 15 days after repetitive injections with DT (Fig. 3B). Analyses based on the GFP expression of regulatory T cells in DEREG mice, showed outgrowth of GFP+FoxP3 regulatory T cells within week 2 (Fig. 3B) as also was described before [24]. However, these GFP+FoxP3 cells were non-functional regulatory T cells. To demonstrate this also in the current study, an in vitro suppression assay was performed after 3 weeks of repetitive DT injections in DEREG mice as a functional analysis of these GFP+FoxP3 regulatory T cells. After isolation of the cells from the...
lymph nodes they were incubated with effector T cells and the effect on effector T cell proliferation was monitored. The GFP$^-$FoxP$^+$ cells had a marked reduced inhibitory effect on T cell proliferation (Fig. 3C).

**Post-ischemic neovascularization in DEREG mice.**

Regulatory T cell-depleted DEREG mice ($n = 22$) showed moderate improvement of blood flow recovery after ischemia induction as compared to control mice ($n = 20$) (Fig. 3D). Nine days after ischemia induction, DEREG mice depleted for regulatory T cells showed 23% improvement of blood flow recovery. However, probably due to high variance, this was not statistically significant. Repetitive DT injections did not have any effect on post-ischemic flow recovery, because flow recovery between C57Bl6 mice with ($n = 10$) and without DT injections ($n = 10$) showed no differences (Fig. S1).

On the tissue level, regulatory T-cell-depleted DEREG mice showed a significant increase of SMA-expressing collateral density in the post-ischemic adductor muscle (Fig. 3E). Furthermore, these mice showed a significantly increase of the CD31$^+$ capillary density of the post-ischemic calf muscles as compared to controls (Fig. 3F). Selective and full depletion of regulatory T cells led to significant increases in capillary and collateral artery formation in the skeletal muscle tissue, but minor improvements of post-ischemic blood flow recovery.
Distribution of regulatory T cells to ischemic area.

The presence of regulatory T cells in the ischemic hind limb was assessed in the ischemic adductor muscle and draining lymph nodes after 3, 7 and 14 days after surgery. Non-depleted DEREG mice had GFP⁺ regulatory T cells, which we traced using immunohistochemistry and flow cytometry analyses. Regulatory T cells were not observed in the skeletal muscle tissue at any time-point examined with immunohistochemical stainings (Fig. 4A). Detailed views of vessel structures in the ischemic adductor muscle did not show any regulatory T cells near collaterals. Moreover, regulatory T cells were present in lymph nodes in the ischemic hind limb.

Compared to lymph nodes of the non-operated hind limb, significant more regulatory T cells were present in the lymph nodes of the ischemic paw (Fig. 4B).

Discussion

In the present study, the contribution of regulatory T cells to the arteriogenic response was studied by analysing the effects of modulation of regulatory T cell levels on arteriogenesis in a mouse.
hind limb ischemia model. Major changes in regulatory T-cell number resulted in only moderate effects on post-ischemic neovascularization, in contrast to what was reported previously [10]. For modulation of regulatory T cell content, more specific approaches were used for a major expansion or complete depletion of regulatory T cells.

Expansion of regulatory T cells was induced by injecting mice with IL-2 mixed with the JES6–1 IL-2 mAB [15]. Unlike most IL-2 mABs, injections of this IL-2-mAB complex led to selective proliferation of regulatory T cells with little or no change in other inflammatory cells making the IL-2-mAB complex superior to other interventions [15]. In the present study, expansion of regulatory T cells resulted in an attenuated blood flow recovery after ischemia induction. Up to 20% suppression of blood flow at day 14 after ischemia induction was observed. These results are in contrast to the major effects of application of this IL-2-mAB complex in various autoimmune disease mouse models, which resulted in the expansion of regulatory T cells in mice leading to a strong resistance to T cell mediated autoimmune disease [15].

In addition to regulatory T cell expansion, we studied the effects of depletion of regulatory T cells on arteriogenesis. Depletion of CD25+ cells with injections of anti-CD25 antibody did not result in any alteration of post-ischemic blood flow recovery as compared to controls. Zouggari et al. [10] did report significant improved blood flow recovery in the absence of regulatory T cells among CD4+ cells in blood of DEREG mice with two DT injections at days 2 and 1 before hind limb ischemia induction. (B) Quantitative flow cytometry analysis of the percentage of GFP+CD4+CD25+FoxP3+ regulatory T cells (left) and GFP+CD4+CD25−FoxP3− regulatory T cells among CD4+ cells in blood during 2 weeks of DEREG mice treated without DT injections, DEREG mice treated with two DT injections (days 2 and 1) and DEREG mice treated with repeated DT injections (4 times a week). (C) In vitro suppression assay after 3 weeks of repetitive DT injections in DEREG mice. After isolation of the regulatory T cells from the lymph nodes they were incubated with effector T cells and the effect on effector T cell proliferation was monitored. Proliferation of effector T cells was significantly enhanced in DEREG mice with DT injections indicating that GFP+ FoxP3+ cells had a strongly reduced inhibitory effect on T cell proliferation. *P < 0.05. (D) The LDPI graph depicts the mean ± S.E.M. of blood flow recovery after double electro-coagulation of the femoral artery and iliac artery in hind limb of DEREG mice injected without (n=22) and with repetitive DT injections (n=20). Blood flow was expressed as ratio between the operated and non-operated limb measured before and directly after surgery and at days 3, 7, 9 and 14. Images on the right depict representative LDPI images of paws of DEREG mice injected without DT (upper) or with DT (lower) 9 days after induction of hind limb ischemia. (E) Histograms depict mean ± S.E.M. of the number of collaterals in the post-ischemic adductor muscle as quantified by SMA labelling (nine sections per muscle were analysed in five animals/treatment group). *P < 0.05. Representative photographs of SMA labelling are shown 14 days after hind limb ischemia induction in DEREG mice without DT injections (left) and DEREG mice with repetitive DT injections (right). Magnification: 10×. (F) The histogram depicts mean ± S.E.M. of the number of capillaries in the post-ischemic calf muscle as quantified by antimouse-specific CD31 labelling (nine sections per muscle were analysed in five animals/treatment group). *P < 0.05. Representative photographs of CD31 labelling are shown 14 days after hind limb ischemia induction in DEREG mice without DT injections (left) and DEREG mice with repetitive DT injections (right). Magnification: 10×.
flow recovery with the same PC61 CD25 depleting antibody 7 and 14 days after ischemia induction. However, in their control mice a 50% flow recovery after 7 days occurred after a single ligature placement of the femoral artery, whereas our control mice show 90–100% recovery after single electro-coagulation of the femoral artery at that time. Differences in the surgical procedure and differences in anaesthesia may explain the observed differences. In the present study, mice were anesthetized with an intraperitoneal injection of a combination of Midazolam, Medetomidine and Fentanyl, whereas Zouggari et al. [10] anesthetized by isoflurane inhalation, which can easily influence vascular tone and thus paw perfusion results. The final proof for the involvement of regulatory T cells in arteriogenesis has not been provided with this approach because CD25 is not exclusively expressed on regulatory T cells, but also on activated T cells [17], NK cells [19] and myeloid DCs [18]. This is of special interest because CD4 T cells [27, 28], CD8 T cells [29] as well as NK cells [27] are known to modulate the arteriogenic response. Along with the fact that there is a CD25 regulatory T cell population [30, 31], a fast return of CD25 cells and reports about the anti-CD25 antibody shedding the epitope rather than depleting these cells [16], the results of studies using this antibody should be interpreted with caution.

Thus, a new approach to fully deplete specifically regulatory T cells within mice is crucial to bypass imperfections of anti-CD25 antibody treatment. A relatively new mouse model, achieving the ablation of cells by genetic introduction of primate DT receptor targeted to specific tissue by the use of a specific promoter, was described in 2001 [32]. Cells of these mice are 10^2–10^5 times more susceptible to DT induced cell death due to their low-affinity DT receptor. Lahl et al. [22] generated DERE5 mice, which allowed direct depletion of FoxP3 cells up to 98% upon DT injections. Importantly, this depletion is not sufficient enough for disease development, as in contrast to FoxP3 knockout mice. FoxP3 knockout mice succumb at young age to lymphoproliferative disease characterized by multiorgan lymphocytic infiltration [33]. The present data showed full depletion of regulatory T cells in DERE5 mice, but only moderate effects on neovascularization. Blood flow improved 23%, 9 days after ischemia in regulatory T cell-depleted DERE5 mice as compared to control DERE5 mice, but this difference was not statistically significant. In addition to LDPI monitoring, immunohistochemical analysis was used to examine neovascularization at tissue level. In line with LDPI data, anti-SMA and anti-CD31 staining of post-ischemic muscles showed an increase in collateral and capillary density in regulatory T cell-depleted DERE5 mice. Zouggari et al. [10] observed significant improved blood flow recovery up to 70% in CD28− mice and B7−1/2− mice, which had a reduced regulatory T cell number and function [8, 10–13]. However, CD28 is the major B7-binding costimulatory...
receptor on T cells and is critical for T cell responses in vivo [14]. CD4+ T-cell and CD8+ T cell responses seemed to be disturbed in these mice too. The interpretation that the observed effects in CD28–/– mice and B7–1/2–/– mice are due to regulatory T cell modulation should be challenged.

To disentangle the mechanism of how regulatory T cells influence the arteriogenic response, the presence of regulatory T cells in the ischemic tissue was studied. No GFP+ regulatory T cells could be detected in post-ischemic adductor muscle in non-depleted DEREG mice with anti-GFP immunohistochemical staining 3, 7 and 14 days after surgery. The absence of regulatory T cells in the ischemic tissue can be related to the only moderate effects of regulatory T cells in arteriogenesis, especially because regulatory T cells are present in the lymph nodes of ischemic (black box) versus non-ischemic (white box) hind limb 14 days after hind limb ischemia induction. *P < 0.05.

In conclusion, the present study demonstrates that regulatory T cells do contribute to the regulation of post-ischemic neovascularization. However, only moderate effects on post-ischemic neovascularization were observed after major modulations of regulatory T cell number.

Acknowledgements

The authors thank H.A.B. Peters for technical assistance and A.C. Foks and J. Kuiper for helping with the expansion of regulatory T cells with IL-2-mAB complex. The authors gratefully acknowledge the financial support of the Translational Excellence in Regenerative Medicine (TeRM) Smart Mix Program of the Netherlands Ministry of Economic Affairs and the Netherlands Ministry of Education, Culture and Science.

Conflict of interest

The authors declare that they have no competing financial interests.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Fig. S1(A) The LDPI graph depicts the mean ± S.E.M. of blood flow recovery after double electro-coagulation of the femoral artery and iliac artery in hind limb of C57Bl6 mice injected without (n = 10) and with repetitive DT injections (n = 10). Blood flow was expressed as ratio between the operated and non-operated limb measured before and directly after surgery and at days 3, 7, 9 and 14. Images on the right depict representative LDPI images of paws of C57Bl6 mice injected without DT (upper) or with DT (lower) 7 days after induction of hind limb ischemia.

Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
References

1. van Weel V, van Tongeren RB, van Hinsbergh VW, et al. Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation. Ann Vasc Surg. 2008; 22: 582–97.

2. van Oostrom MC, van Oostrom O, Quax PH, et al. Insights into mechanisms behind arteriogenesis: what does the future hold? J Leukoc Biol. 2008; 84: 1379–91.

3. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005; 6: 345–52.

4. Ait-Oufella H, Salomon BL, Potteaux S, et al. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004; 22: 531–62.

5. van Es T, van Puijvelde GH, Foks AC, van Weel V, van Tongeren RB, van Oostrom MC, et al. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells control the arteriogenic response to ischemia by infiltrating the site of collateral artery development. Arterioscler Thromb Vasc Biol. 2008; 28: 2406–15.

6. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol. 2005; 6: 353–60.

7. Driesen J, Popov A, Schultze JL. CD25 as an immune regulatory molecule expressed on myeloid dendritic cells. Immunobiology. 2006; 211: 13–23.

8. Zoungari Y, Ait-Oufella H, Waecel K, et al. Regulatory T cells in atherosclerosis. Trends Cardiovasc Med. 2007; 17: 113–8.

9. Zoungari Y, Ait-Oufella H, Waecel K, et al. Regulatory T cells modulate postischemic neovascularization. Circulation. 2009; 120: 1451–55.

10. Tang Q, Henrikson KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol. 2003; 170: 3348–52.

11. Tang Q, Smith JA, Zlot GL, et al. CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo. J Immunol. 2003; 170: 1510–6.

12. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000; 12: 431–40.

13. Mak T.W. CD28. In: Tak W. Mak, editor. The gene knockout factsbook. A-H. London: Academic Press; 1998. p.161–4.

14. Webster KE, Walters S, Kohler RE, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med. 2009; 206: 751–60.

15. Kohm AP, McMahon JS, Podoljik JR, et al. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ regulatory cells. J Immunol. 2006; 176: 3301–5.

16. Shibata K, Yamada H, Nakamura R, et al. Identification of CD25− gamma delta T cells as foetal thymus-derived naturally occurring IL-17 producers. J Immunol. 2008; 181: 5940–7.

17. Moazed D, Elkharrat I, Philpott DJ, et al. Identification of CD25+ regulatory T cells in spontaneously regenerating T cells expressing CD25 as a marker identifies unique subsets of CD25+ T lymphocytes that prevent autoimmune diabetes. Immunity. 2000; 12: 431–40.

18. Mak T.W. CD28. In: Tak W. Mak, editor. The gene knockout factsbook. A-H. London: Academic Press; 1998. p.161–4.

19. Webster KE, Walters S, Kohler RE, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med. 2009; 206: 751–60.

20. Kohm AP, McMahon JS, Podoljik JR, et al. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ regulatory cells. J Immunol. 2006; 176: 3301–5.

21. Shibata K, Yamada H, Nakamura R, et al. Identification of CD25− gamma delta T cells as foetal thymus-derived naturally occurring IL-17 producers. J Immunol. 2008; 181: 5940–7.

22. Becknell B, Caligiuri MA. Identification of CD25+ regulatory T cells with this function are found in both CD4+ and CD8+ T lymphocytes regulate the arteriogenic response to ischemia by infiltrating the site of collateral vessel development and recruiting CD4+ mononuclear cells through the expression of interleukin-16. Circulation. 2006; 113: 118–24.

23. Stephens LA, Mason D. CD25 is a marker for CD4+ T lymphocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD8+ T cells. J Immunol. 2000; 165: 3105–10.

24. Lehmann J, Huehn J, de la Rosa M, et al. Expression of the integrin alpha E betta 7 identifies unique subsets of CD25+ as well as. Proc Natl Acad Sci USA. 2002; 99: 13031–6.

25. Saito M, Iwawaki T, Taya C, et al. Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat Biotechnol. 2001; 19: 746–50.

26. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/ winged-helix protein, scurf, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001; 27: 68–73.